S Matthes
About
In The Last Decade
S Matthes
16 papers receiving 367 citations
Peers
Comparison fields: 5 of 62
- Oncology 207
- Pulmonary and Respiratory Medicine 97
- Cancer Research 77
- Pathology and Forensic Medicine 66
- Hematology 62
Countries citing papers authored by S Matthes
This map shows the geographic impact of S Matthes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S Matthes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S Matthes more than expected).
Fields of papers citing papers by S Matthes
This network shows the impact of papers produced by S Matthes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S Matthes. The network helps show where S Matthes may publish in the future.
Co-authorship network of co-authors of S Matthes
This figure shows the co-authorship network connecting the top 25 collaborators of S Matthes. A scholar is included among the top collaborators of S Matthes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S Matthes. S Matthes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 5 | |
| 2 | 3 | |
| 3 | 4 | |
| 4 | 2 | |
| 5 | 69 | |
| 6 | Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. | 35 |
| 7 | Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea. | 23 |
| 8 | 40 | |
| 9 | 53 | |
| 10 | Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience. | 12 |
| 11 | High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial. | 38 |
| 12 | 12 | |
| 13 | 1 | |
| 14 | 2 | |
| 15 | 67 | |
| 16 | 16 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.